Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZDN4W)

Drug Name

L-Alanine Drug Info

Synonyms

ALA; Alaninum; LPG; Polyalanine; A-Alanine; A-Aminopropionic acid; Alanina [DCIT,Spanish]; Alanine (USP); L-A-Aminopropionicacid; L-Alanine (9CI); L-Alanine (JAN); L-Alanine, homopolymer; L-Alanine, labeled with tritium; L-a-Alanine; L-a-Aminopropionic acid; Poly-DL-alanine; L-Alanine, labeled with carbon-14; Alanine, L-(7CI,8CI); F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine, N-coco alkyl derivs.; Propanoic acid, 2-amino-, (S); (C14)L-Alanine; (S)-2-Aminopropionic acid; 14C-L-Alanine

Indication

Disease Entry	ICD 11	Status	REF
Dietary shortage	5B5K	Approved	[1]
Glioma	2A00.0	Approved	[1]

Therapeutic Class

Dietary supplement

Cross-matching ID

PubChem CID: 5950
ChEBI ID: CHEBI:16977
CAS Number: CAS 56-41-7
TTD Drug ID: DMZDN4W
VARIDT Drug ID: DR00142

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting GABA transaminase (ABAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[2]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[2]
Vigabatrin	DMYT0OG	Alcohol dependence	6C40.2	Approved	[6]
Divalproex sodium	DM4RK0G	Seizure disorder	8A6Z	Approved	[2]
CPP-115	DMK9NQI	Tourette syndrome	8A05.00	Phase 2	[7]
K-828-AB	DMJLNZQ	Dementia	6D80-6D86	Phase 2	[8]
CPP -15	DMQCHU3	Infantile spasm	8A62.0	Phase 1	[7]
T83193	DMHO29Y	Discovery agent	N.A.	Patented	[9]
4-hydroxybenzaldehyde	DM471P5	Discovery agent	N.A.	Patented	[10]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[5]
------------------------------------------------------------------------------------

Drug(s) Transported By Sodium-coupled neutral amino acid transporter 1 (SLC38A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[3]
------------------------------------------------------------------------------------

Drug(s) Transported By Sodium-coupled neutral amino acid transporter 2 (SLC38A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[3]
------------------------------------------------------------------------------------

Drug(s) Transported By Sodium-coupled neutral amino acid transporter 3 (SLC38A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[12]
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[3]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[13]
------------------------------------------------------------------------------------

Drug(s) Transported By Sodium-coupled neutral amino acid transporter 4 (SLC38A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[3]
------------------------------------------------------------------------------------

Drug(s) Transported By Sodium-coupled neutral amino acid transporter 5 (SLC38A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[3]
------------------------------------------------------------------------------------

Drug(s) Transported By L-type amino acid transporter 2 (SLC7A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[4]
Glycine	DMIOZ29	Allergic rhinitis	CA08.0	Approved	[4]
L-Proline	DMKSTWR	Malnutrition	5B50-5B71	Approved	[4]
L-Phenylalanine	DMQXI9F	Malnutrition	5B50-5B71	Approved	[14]
L-Tyrosine	DM9O8DT	Malnutrition	5B50-5B71	Approved	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-coupled neutral amino acid transporter 3 (SLC38A3)	DTKWJH3	S38A3_HUMAN	Substrate	[3]
Sodium-coupled neutral amino acid transporter 5 (SLC38A5)	DTLX28N	S38A5_HUMAN	Substrate	[3]
Sodium-coupled neutral amino acid transporter 4 (SLC38A4)	DTPJBD5	S38A4_HUMAN	Substrate	[3]
Sodium-coupled neutral amino acid transporter 2 (SLC38A2)	DTTWL58	S38A2_HUMAN	Substrate	[3]
Sodium-coupled neutral amino acid transporter 1 (SLC38A1)	DTD815L	S38A1_HUMAN	Substrate	[3]
L-type amino acid transporter 2 (SLC7A8)	DTJF3DX	LAT2_HUMAN	Substrate	[4]
Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)	DTC54PX	SATT_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 720).
2	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
3	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
4	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
5	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
6	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7	Clinical pipeline report, company report or official report of Catalyst Pharma.
8	Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
9	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
10	Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
11	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
12	Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem Pharmacol. 1995 Jun 16;49(12):1759-67.
13	Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66.
14	Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.